Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 8/20 | 0.40 |
| ▸ | TLR2 | O60603 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | APLNR | P35414 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1943594 | 0.93 | TLR2 (0.39) | P2RX7TLR2POLBALDH1A1ADORA2A | |
| SCHEMBL1943735 | 0.92 | PIK3CD (0.39) | P2RX7TLR2POLBALDH1A1ADORA2A | |
| SCHEMBL1943596 | 0.86 | TLR2 (0.42) | P2RX7TLR2POLBALDH1A1ADORA2A | |
| SCHEMBL1944795 | 0.86 | POLB (0.39) | POLBALDH1A1GAATDP1SCN9A | |
| SCHEMBL1944144 | 0.85 | P2RX7 (0.39) | P2RX7TLR2POLBALDH1A1GAA | |
| SCHEMBL1942934 | 0.84 | P2RX7 (0.38) | P2RX7TLR2POLBALDH1A1ADORA2A | |
| SCHEMBL1941900 | 0.83 | POLB (0.38) | P2RX7TLR2POLBALDH1A1ADORA2A | |
| SCHEMBL1943749 | 0.83 | POLB (0.35) | P2RX7TLR2POLBALDH1A1ADORA2A | |
| SCHEMBL1943748 | 0.82 | USP14 (0.40) | P2RX7TLR2POLBALDH1A1GAA | |
| SCHEMBL1943763 | 0.82 | APLNR (0.42) | POLBALDH1A1ADORA2AADORA1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110130407-A1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | H. LUNDBECK A/S (DK) | 2011-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130407-A1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | KCNQ3, KCNK3, GRIK3 | P2RX7 1005/4885TLR2 2923/4885POLB 3624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.